BackParabilis Medicines Overview
Parabilis Medicines, Inc.

Parabilis Medicines Target Price

Analysts' average 12-month price target for Parabilis Medicines is $40.

Get informed when a big investor buys or sells

+ Follow

Share Price

$37.22

Average Target Price

$40.007.5% upside

2 analysts in the last 4 months

High: $40 | Low: $40

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-06Leerink Partners$407.5% upsideOpen
2026-07-06Guggenheim$407.5% upsideOpen

Parabilis Medicines (PBLS) FAQ

Parabilis Medicines posts a target price of $40. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $40 for PBLS means covering analysts, on average, see the stock 7.5% upside of $37.22 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for PBLS's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Parabilis Medicines's other metric pages and overview cover the third.

Judging Parabilis Medicines against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $40 here, then scan peer and history charts to see if the gap is persistent.